Paratus Sciences

About

Paratus Sciences is a biotechnology startup founded in 2021, focused on discovering and developing therapeutics for human diseases by leveraging bat biology, genomics, and informatics. Headquartered in New York, with operations in Boston/Cambridge, NYC, and Singapore, the company was established by researchers from NUS, MIT, and Mount Sinai Health System. Paratus aims to translate bat evolutionary adaptations, such as resistance to inflammation and metabolic stress, into solutions for human health. The company operates an integrated discovery platform that combines genomics and multi-omics data to identify drug targets by comparing bat disease patterns with those in humans. Paratus's primary focus is on immunological, inflammatory, and cardiometabolic conditions, with potential expansion into oncology and aging. They utilize advanced data-driven processes for target identification and validation, and they foster collaborations with academic and research institutions to enhance bat research and innovation. Notable investors include ClavystBio, Polaris Partners, Leaps by Bayer, and Alexandria Venture Investments, supporting their growth and development efforts.